Bio-Path (BPTH) Stock Price, News & Analysis

Company Overview

Bio-Path Holdings, Inc. (NASDAQ:BPTH) is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for cancer and other serious diseases. The company’s platform centers on its proprietary Liposomal DNA Antisense Technology (LDAT), which leverages liposome-based delivery to transport antisense DNA molecules directly into targeted cells. By silencing specific messenger RNAs (mRNAs) associated with disease, Bio-Path aims to modulate pathways that drive tumor growth and survival.

The company’s lead investigational therapy, prexigebersen (BP1001), is designed to inhibit Grb2 mRNA, a critical adaptor protein involved in multiple oncogenic signaling pathways. Prexigebersen has been evaluated in early- and mid-stage clinical trials in patients with acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), and select solid tumors. In addition to prexigebersen, Bio-Path’s pipeline includes BP1002, an antisense candidate targeting BCL-2 mRNA to promote cancer cell apoptosis, and other preclinical programs exploring additional oncogenic targets.

Bio-Path conducts its clinical studies primarily in the United States, collaborating with major cancer centers to evaluate safety, pharmacokinetics, and preliminary efficacy across hematologic and solid tumor indications. The company aims to advance its most promising candidates through pivotal trials and regulatory filings, either independently or via strategic partnerships, to bring new treatment options to patients with high unmet medical needs.

Headquartered in Houston, Texas, Bio-Path is led by Founder, Chairman and Chief Executive Officer Francisco J. Hernandez, who brings extensive experience in biopharmaceutical research and development. The management team combines scientific expertise and clinical development know-how to drive the company’s translational programs from the laboratory into the clinic. Bio-Path continues to leverage its LDAT platform to expand its pipeline and explore novel applications of antisense technology in oncology and beyond.

Key Stats

• Today's Range: $0.04 to $0.04
• 50-Day Range: $0.03 to $0.05
• 52-Week Range: $0.01 to $0.15
• Volume: 5,350 shs
• Average Volume: 23,569 shs
• Market Capitalization: $2.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 8/15/2024
• Today: 8/14/2026
• Next Earnings (Estimated): 8/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:BPTH
• CIK: 1133818
• Web: www.biopathholdings.com
• Phone: (832) 742-1357
• Fax: N/A
• Employees: 10
• Year Founded: 2007

Profitability

• EPS (Trailing Twelve Months): ($1.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.08 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -2,842.40%
• Return on Assets: -337.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.86
• Quick Ratio: 0.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.71 per share
• Price / Book: 0.06

Miscellaneous

• Outstanding Shares: 51,339,000
• Free Float: 5,726,000
• Market Cap: $2.08 million
• Optionable: No Data
• Beta: -0.51